Skip to Content

    Two drugs for hepatitis C, Harvoni and Sovaldi, helped sales top $7 billion during the final quarter of 2014 for this biopharma company.

    Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

    Company Information

    Location
    Foster City, CA
    Industry
    Pharmaceuticals
    Sector
    Health Care
    Fortune 500 Rank118
    Fortune 500 Profilehttp://fortune.com/fortune500/gilead-sciences-118/
    Current Streak1
    Years on List6
    CEO
    John C. Martin
    Websitehttp://www.gilead.com

    Revenue, Net Income

    Revenue Past Four Quarters27,485
    Net Income Past Four Quarters14,207

    Growth Rates

    EPS 3 yr Annual Growth Rate67%
    Rev 3 yr Annual Growth Rate43%
    Total Return 3 yr Annual Rate66%
    Beat S&P 3 yr Total Return?
    yes

    Rank

    EPS Growth Rank32
    Revenue Growth Rank21
    Total Return Rank
    21